Sweet Potato Buddha Bowl Video
Find out how to make this well-balanced, colorful sweet potato and chickpea buddha bowl from Taking Cancer on Through Flavour and Taste Life.
Search
berrysmoothie video
We show you how easy it is to make the berry smoothie from our Taking Cancer on Through Flavour initiative. Follow along and make it at home!
Anna Race
Anna Race, Sales Director, Human Pharma, UK & Ireland, tells us how a career in our Commercial Division helps her to make a difference.
Work life balance
It's important that employees have a balance between professional and personal lives, so we offer various leave options and flexible working schedules.
The unseen lameness problem in horses
Learn more about the signs, causes and preventive measures of lameness in horses.
The GPP Charter
The GPP Charter defines a collaborative approach to identifying common goals for the GPP community
IPF why wait?
IPF is a progressive and life threatening lung disease that can cause permanent damage in the lungs right from the start. Early diagnosis and treatment of IPF is critical, because acting quickly can make a difference.
Cardiometabolic Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
real-world-benefit-shown-in-T2D-treatment
Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
emperor-reduced-chmp-positive-opinion
CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction
EMPA-KIDNEY trial early stop due to positive efficacy
EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy
Striving to revolutionize mental health research
World Mental Health Day: Through a precision psychiatry approach and rich pipeline, we are committed to transforming the mental health landscape.
reduced-heart-failure-treatment-approval-europe
European approval for treatment of adults with heart failure with reduced ejection fraction
Digital Therapeutic
Digital Therapeutic
New data for nintedanib in children with fibrosing ILD
InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
FDA-CRL-T1D
US FDA issues complete response letter for treatment of adults with type 1 diabetes
Covid19 relief program Ghana Cowtribe parasiticides
Boehringer Ingelheim and Cowtribe are kicking off a vital relief initiative in Ghana.
How fast can a cheetah run wild and free?
Cheetahs’ top speed can reach up to 120km/h. But habitat loss, illegal wildlife trade and hunting made these impressive animals critically endangered.
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
Vicadrostat (BI 690517) + empagliflozin
The chronic nature of generalized pustular psoriasis
Understanding the impact of the physical and psychological symptoms of this chronic disease.
FDA-Fast-Track-chronic-kidney-disease
FDA grants Fast Track designation for the treatment of chronic kidney disease, underscoring urgent need for new treatments for people living with the condition
emperor-reduced-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction
preserved-heart-failure-treatment-approval-europe
preserved-heart-failure-treatment-approval-europe
DCRI-collaboration-empact-mi
Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction